CompletedPhase 3NCT01812551
Treatment of Low Bone Density in Cystic Fibrosis.
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Istituto Auxologico Italiano
- Principal Investigator
- Maria Luisa Bianchi, M.D.Istituto Auxologico Italiano
- Intervention
- Alendronate(drug)
- Enrollment
- 171 enrolled
- Eligibility
- 5-30 years · All sexes
- Timeline
- 2002 – 2007
Study locations (11)
- CRR Fibrosi Cistica, Divisione Gastroenterologia, Ospedale Bambin Gesù, Vatican City, Holy See
- CRR Fibrosi Cistica, Unità Operativa di Pediatria, Ospedale Misericordia, Grosseto, Italy
- CRR Fibrosi Cistica, Clinica Pediatrica, Policlinico Universitario di Messina, Messina, Italy
- Istituto Auxologico Italiano IRCCS, Milan, Italy
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy
- CRR Fibrosi Cistica, Dipartimento Pediatria, Università Federico II, Naples, Italy
- CRR Fibrosi Cistica Adulti, Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, Italy
- CRR Fibrosi Cistica, Ospedale dei Bambini, ARNAS Civico, Palermo, Italy
- CRR Fibrosi Cistica, Dipartimento di Pediatria, Policlinico Umberto I, Roma, Italy
- CRR Fibrosi Cistica, Divisione di Pediatria, Istituto Burlo Garofolo, Trieste, Italy
- CRR Fibrosi Cistica, Azienda Ospedalierouniversitaria di Verona, Verona, Italy
Collaborators
Fondazione Telethon
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01812551 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.
- RECRUITINGPHASE1NCT07283770Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNCT07363304Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.Meyer Children's Hospital IRCCS